Return to homepagePandemic Pact

Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic and the Role of State Policy Changes

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2021
    2022

  • Known Financial Commitments (USD)

    $358,422

  • Funder

    FORE

  • Principal Investigator

    MD. Bradley Stein

  • Research Location

    United States of America

  • Lead Research Institution

    RAND Corporation

  • Research Priority Alignment

    N/A

  • Research Category

    Secondary impacts of disease, response & control measures

  • Research Subcategory

    Indirect health impacts

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Drug users

  • Occupations of Interest

    Unspecified

Abstract

This project will investigate changes in buprenorphine prescribing during the pandemic and how these changes may have affected access to care and treatment outcomes among underserved populations, including Medicaid beneficiaries and rural populations. The investigator will explore how the observed changes in prescribing relate to different state policies. The analysis will inform decisions about whether to continue or adapt COVID-era policies intended to preserve access to treatment.